- Home
- INTR vs AGIO Comparison
INTR vs AGIO Comparison
Compare INTR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- AGIO
- Stock Information
- Founded
- INTR 1994
- AGIO 2007
- Country
- INTR Brazil
- AGIO United States
- Employees
- INTR N/A
- AGIO N/A
- Industry
- INTR
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- INTR
- AGIO Health Care
- Exchange
- INTR Nasdaq
- AGIO Nasdaq
- Market Cap
- INTR 2.6B
- AGIO 3.0B
- IPO Year
- INTR N/A
- AGIO 2013
- Fundamental
- Price
- INTR $5.54
- AGIO $55.54
- Analyst Decision
- INTR Strong Buy
- AGIO Buy
- Analyst Count
- INTR 4
- AGIO 7
- Target Price
- INTR $7.45
- AGIO $52.33
- AVG Volume (30 Days)
- INTR 1.4M
- AGIO 737.4K
- Earning Date
- INTR 11-14-2024
- AGIO 10-31-2024
- Dividend Yield
- INTR 2.16%
- AGIO N/A
- EPS Growth
- INTR 295.93
- AGIO N/A
- EPS
- INTR 0.33
- AGIO 11.80
- Revenue
- INTR $767,729,562.00
- AGIO $32,871,000.00
- Revenue This Year
- INTR N/A
- AGIO $33.38
- Revenue Next Year
- INTR $24.22
- AGIO $163.06
- P/E Ratio
- INTR $16.63
- AGIO $4.70
- Revenue Growth
- INTR 38.44
- AGIO 36.79
- 52 Week Low
- INTR $4.32
- AGIO $20.96
- 52 Week High
- INTR $7.84
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- INTR 31.76
- AGIO 62.15
- Support Level
- INTR $5.78
- AGIO $52.09
- Resistance Level
- INTR $6.78
- AGIO $62.58
- Average True Range (ATR)
- INTR 0.23
- AGIO 2.85
- MACD
- INTR -0.07
- AGIO -0.06
- Stochastic Oscillator
- INTR 5.70
- AGIO 63.58
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.